Urothelial Carcinoma Highlights
|
|
- Erika Warner
- 5 years ago
- Views:
Transcription
1 Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation
2 Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra Zeneca, Pfizer, Astellas/Seattle Genetics, Clovis Oncology Travel, Accommodations, Expenses: Company: Roche, Merck & Co. Inc., Pierre Fabre, PeerVoice Research Funding (Institution): Company: Merck & Co. Inc., Astra Zeneca, Amgen
3 Presentation objectives Review updated anti-pdl1/pd1 trial data and the design of trials in non-metastatic UBC Gain insights on the impact of the data in the future treatment landscape of GU cancers Review emerging novel biomarkers Powles T, Necchi A, Rosen G, et al. CGUC 2017
4 1L metastatic setting
5 Phase II IMvigor210 & KN052 Study Design and Objectives Inoperable locally advanced or metastatic UC Predominantly UC histology Tumor tissue evaluable for PD-L1 testing Cohort 1 (N = 119): 1L cisplatin ineligible Cohort 2: Platinum-treated muc Atezolizumab 1200 mg IV q3w until RECIST v1.1 progression Atezolizumab 1200 mg IV q3w until loss of clinical benefit Key cohort 1 inclusion criteria: No prior treatment for muc (> 12 months since perioperative chemotherapy) ECOG PS 0-2 Cisplatin ineligibility based on 1 of the following: 1 GFR < 60 and > 30 ml/min (Cockcroft-Gault), Grade 2 hearing loss (25 db at 2 contiguous frequencies) or peripheral neuropathy, ECOG PS 2 Endpoints: Primary: confirmed ORR per RECIST v1.1 (central IRF) Key secondary: DOR, OS, safety Balar AV et al, Lancet Jan 7;389(10064):67-76 Balar AV, et al. Lancet Oncol 2017; /S (17)
6 How Emerging Clinical Data Will Impact the European/US Treatment Algorithm for Metastatic Urothelial Cancer FIRST LINE 1,2 Eligible for cisplatin? Yes PS 0-1 GFR 60 ml/min Standard chemotherapy: GC, MVAC, HD-MVAC, PCG PS 2 or GFR <60 ml/min Combination chemotherapy: Carboplatin-based Immune checkpoint inhibitor 3 No PS 2 and GFR <60 ml/min NO combination chemotherapy: Monotherapy, BSC Immune checkpoint inhibitor 3 Consider clinical trial of new or more tolerable therapy 3 SECOND LINE 1,2 PS 0-1 Consider immune checkpoint inhibitor therapy 3 PS 2 Standard second-line chemotherapy BSC Consider clinical trial BSC: best supportive care; GFR: glomerular filtration rate; (HD-)MVAC: (high-dose) methotrexate, vinblastine, doxorubicin, cisplatin; PCG: paclitaxel, cisplatin, gemcitabine. 1. Witjes JA et al. Eur Urol. 2017;71: Witjes JA et al. -Muscle-invasive-and-Metastatic-Bladder-Cancer-Guidelines-2016.pdf. Published Accessed March 3, National Comprehensive Cancer Network (NCCN). Bladder Cancer (Version ). Accessed February 9, 2017.
7 Recruiting Clinical Trials: First-Line Metastatic Bladder Cancer Study Agent Phase and Type Pembrolizumab ± MK / KEYNOTE chemotherapy a vs chemotherapy IMvigor130 2 Atezolizumab ± chemotherapy a DANUBE 3 CheckMate901 4 Galsky MD et al. TPS 539 vs chemotherapy 3 Randomised, controlled 3 Randomised, controlled Durvalumab ± tremelimumab vs SOC chemotherapy 3 Randomised, open label Nivolumab+Ipilimumab vs chemotherapy 3 Randomised, open label Primary Endpoint a GEM-CIS or GEM-carboplatin. SOC: standard of care. 1. ClinicalTrials.gov Identifier: NCT Accessed February 27, ClinicalTrials.gov Identifier: NCT Accessed February 27, ClinicalTrials.gov Identifier: NCT Accessed September 14, ClinicalTrials.gov Identifier: NCT Accessed September 14, 2017 PFS, OS PFS, OS, % with AEs PFS, OS PFS, OS
8 Necchi A, et al. Abstr. #426
9 Summary of the evidences with the use of ICI in first-line therapy Atezolizumab and pembrolizumab are well-tolerated and durable responses are seen in UC patients who are not eligible for cisplatin-based chemotherapy (US-FDA & EMA Approved). However randomised data on the benefit in this setting does not exist If clinical trials are not available and registration permits, treatment with atezolizumab or pembrolizumab could be considered for cisplatin-ineligible first-line patients In candidates for cisplatin-based therapy, there is currently no data to support use of checkpoint inhibitors as first-line treatment outside of clinical trials Currently, there is no evidence supporting the PD-L1 biomarker for selecting patients for ICI therapy in chemotherapy-naive patients SUGGESTION FROM ASCO-GU 2018: Early shift toward second-line immunotherapy or novel agents is recommended (do not administer >4 cycles of platinum-chemo)
10 2L metastatic setting
11 Outcomes of IMvigor211 - Efficacy US FDA and EMA approval for platinum-treated, advanced UC Powles T. et al, Lancet 2017 & GU-ASCO 2018
12 Outcomes of IMvigor211 - Biomarkers Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
13 Outcomes of IMvigor211 - Biomarkers Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
14 Outcomes of IMvigor211 - Biomarkers Presented By Thomas Powles at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
15 Mariathasan S, et al. Nature 2018
16 Overall Survival, % KN-045: Overall Survival: Total % 29.8% 27.0% 14.3% No. at risk Time, Months Pembro Chemo Median (95% CI): 10.3 months ( ) 7.3 months ( ) Bellmunt J, et al. Abstr. #410
17 Progression Free Survival, % KN Progression-Free Survival: Total CheckMate-032 PFS Update % 9.5% 12.5% 2.5% Median PFS (95% CI): 3.3 months ( ) 2.1 months ( ) 0 Pembro Chemo Time, Months Sharma P, et al. Abstr. #414 Bellmunt J, et al. Abstr. #410
18 Comparison of main outcomes from the Phase 3 trials IMVIGOR211 1 KEYNOTE452 2 Study drug atezolizumab pembrolizumab Number of patients receiving study drug PS 2 0 1% Bladder primary 69% 86% Liver metastasis 30% 34% Patients with 2 or more risk factors 23% 41% Visceral metastasis 77% 89% 2 or more previous lines of therapy 19% 20% Vinflunine use in control arm 54% 34% PD-L1 positive patients 25% 40% Response rate in ITT 13% 21% OS is PD-L1 postives 0.87 (95%CI: ) 0.59 (95%CI: ) Response rates in PD-L1 positives 23% 22% Overall survival in all comers 0.85 (95% CI: (95%CI: ) 1. Powles T. et al, ASCO-GU 2018; 2. Bellmunt J, et al. ASCO-GU 2018
19 New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab Presented By Gregory Pond at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
20 Pond GR, et al. Abstr. #451
21 Summary 2L Findings confirm that clinical benefit with ICI use is maintained at long term Clinical prognostic factor models derived from noncomparative trials did support the benefit from ICI therapy compared to standard chemotherapy Results from translational studies will likely provide the basis for understanding patient outcome in this setting
22 Ongoing immunotherapy trials as proofof-concepts in early-stage disease
23 Necchi A, et al. Abstr. #TPS533 Necchi A, et al. Abstr. #TPS534 Gupta S, et al. Abstr. #TPS528 Geynisman DM, et al. Abstr. #TPS537
24 Harnessing the neoadjuvant platform in Muscle-Invasive Urothelial Bladder Cancer: the Milano model CT scan, 18 FDG-PET/CT scan mpmr of the bladder Non-responding, Cisplatineligible pts: DD-MVAC x 3 Patients with histologically confirmed TCC (T2-T4a) of the bladder 3 3 weekly cycles of pembrolizumab 200 mg* Cystectomy Post-cystectomy management according to local guidelines Study visits at 4, 12, 24 wks after surgery Survival data collected until 2 y post cystectomy CT scan, 18 FDG-PET/CT scan mpmr of the bladder *Enrolling: PURE01 trial: Primary Endpoint: Pathologic CR rate in T2-T4a N0M0 UBC; N=90 Briganti A, et al. EAU 2018; Necchi A, et al. AUA 2018, AACR 2018
25 Can we predict response and survival after neoadjuvant chemotherapy? Biomarker N Translational relevance Reference ERCC2 mutation 50 Association with pathologic response Van Allen EM, Cancer Discov 2014 ERCC2 mutation Association with improved OS in 2 independent cohorts of cisplatin-treated MIBC patients Liu, et al. JAMA Oncol 2016 Plimack ER et al, Eur Urol 2015 Plimack ER et al, ASCO 2014 ATM/RB1/FANCC mutations 34 Association with improved pt<2 response and OS Plimack ER et al, Eur Urol 2015 ERBB2 mutations 71 Association with pt0 response Groenendijk FH et al, Eur Urol 2015 DNA damage response (DDR) gene alterations 34 Association with pt0/ptis response to DD-GC Iyer G et al, ASCO 2016 Single-sample genomic subtyping classifier 343 Basal tumors benefited the most from neoadjuvant chemotherapy administration Seiler R et al, Eur Urol 2017
26 Geynisman DM, et al. Abstr. #TPS537 Presented By Seth Lerner at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
27 Presented By Seth Lerner at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
28 Ongoing Phase 3 Trials: Postoperative Setting for High-Risk Patients With Bladder or Upper Tract Urothelial Cancer Study Agent ClinicalTrials.gov Identifier PD-L1 Selection Standard Arm IMvigor010 Atezolizumab NCT No Observatio n CheckMate 274 Primary Endpoint Sample Size DFS 700 Nivolumab NCT No PBO DFS 600 Ambassador Pembrolizumab NCT No Observatio n DFS/OS 739 DFS: disease-free survival; PBO: placebo; TBD: to be determined.
29 Ongoing neoadjuvant trials for non-metastatic UTUC: Agents Sponsor ClinicalTrials.gov Identifier Gem-Cis Durvalumab + Tremelimumab Xiangya Hospital of Central South University MDACC, MedImmune NCT NCT Gem-Cis MSKCC NCT Patient Selection High grade UTUC High risk UTUC, CDDPineligible High grade UTUC Design Single arm Phase 2 Primary Endpoint Sample Size OS 50 Single arm Phase 2 Safety 15 Single arm Phase 2 Path Response 54 Gem-Carbo; DD-MVAC ECOG-ACRIN NCT High grade UTUC Non-randomized Phase 2 pcr 60
30 Biomarker findings & New drugs
31 IMvigor210: TCGA Subtype in muc Immune desert Luminal Basal I II III IV Papillary like Squamous Mesenchymal Inflamed Immune suppressed a Response IC status TC status IMvigor210 subtypes have distinct tumor-immune landscapes that reflect responsiveness to atezolizumab Tumor stroma Tumor cells TIL/immune cells Increased responses TIL, tumor-infiltrating lymphocyte. a High myeloid, inflammatory, activated stromal/fibroblast markers. Data cutoff: March 14, Rosenberg J et al, ASCO 2016
32 Is FGFR Mut/Fus a favorable feature in MIBC? Robertson et al., 2017, Cell 171, 1 17 McConkey D, et al. Hematol Oncol Clin North Am. 2015;29: ; Sharma P, et al. Lancet Oncol. 2017;18: ; Rosenberg JE, et al. Lancet. 2016;387: ; Balar AV, et al. Lancet. 2017;389:67-76; Siefker-Radtke AO, et al Genitourinary Cancers Symposium, Abstr 450
33 Nassar A, et al. Abstr. #465
34 Maximum Reduction From Baseline (%) Most Patients Receiving 8 mg Continuous Dose Erdafitinib Had Tumor Shrinkage 100 FGFR Mutation FGFR Fusion Regimen 1 10 mg intermittent dose Regimen 2 6 mg continuous dose Regimen 3 8 mg continuous dose Evaluable patients, n ORR confirmed, n (%) CR PR SD 8 (24) 2 (6) 6 (18) 16 (49) 27 (35) 2 (3) 25 (32) 30 (39) 25 (42) 3 (5) 22 (37) 23 (39) Total 60 (35) 7 (4) 53 (31) 69 (41) DCR confirmed, n (%) 24 (73) 57 (73) 48 (81) 129 (76) DoR, median months PFS, median months Survival rate at 1 year 31% 32% 57% 38% Patient Loriot Y, et al. Abstract
35 Responses Were Maintained mg Treatment ongoing Treatment discontinuation Among patients receiving 8 mg continuous dose erdafitinib: 42% of patients had an objective response Median DoR was 5.4 months Many responses are ongoing Responder (confirmed CR/PR) Uptitrated patient Complete response Partial response Stable disease Progressive disease 0 20 Weeks Loriot Y, et al. Abstract 411 6
36 Joeger M, et al. Abstr. #494
37 Patient journey and therapeutic options across the clinical stages MIBC/1L metastatic Neoadjuvant/A djuvant/1l Cisplatin-base chemo first Cisineligible/treate d pts, FGFRmutation/fusio n + tumor pan-fgfr inhibitor-first? Cisineligible/treate d pts, FGFR wild-type tumors ICI first option (IO combo?) ICI progression, FGFR wild-type Ramucirumabdocetaxel first 1 Continue ICI Salvage chemo FGFR: fibroblas growth-factor receptor; ICI: immune checkpoint inhibitors; IO: immuneoncology; MIBC: muscle-invasive bladder cancer 1. Petrylak DP, et al. Lancet Sep 12. pii: S (17)
38 @AndreaNecchi
Options for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationNeoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationDisclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationNeoadjuvant and adjuvant therapy: Current indications, trials, and patient selection
Neoadjuvant and adjuvant therapy: Current indications, trials, and patient selection Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy European Association of Urology Research
More informationExploring New Strategies in Bladder Cancer
Exploring New Strategies in Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, Genitourinary Translational Working Group Co-Director, Signal Transduction Program Smilow Cancer
More informationChallenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
More informationAdvanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
More informationImmunoterapia nella malata avanzata. Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano
Immunoterapia nella malata avanzata Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano Five checkpoint inhibitors now approved for UC! BCG Atezolizumab (US/EU) (2L) Atezolizumab (US/EU)
More informationIntegrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationOptimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
More informationTreatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationApproved checkpoint inhibitors in bladder cancer: which drug should be used when?
788310TAM0010.1177/1758835918788310Therapeutic Advances in Medical OncologyP Ghatalia, M Zibelman research-article20182018 Therapeutic Advances in Medical Oncology Review Approved checkpoint inhibitors
More informationCancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable
Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationI Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
I Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena XII Corso di aggiornamento AIRTUM per operatori dei Registri Tumori Reggio Emilia
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationLa realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga
La realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre. I +
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationEmerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Current Oncology Reports (2018) 20:48 https://doi.org/10.1007/s11912-018-0693-y GENITOURINARY CANCERS (DP PETRYLAK AND JW KIM, SECTION EDITORS) Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationRECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer IX CIS and EURASIA ONCOLOGY and RADOLOGY CONGRESS, ONCOUROLOGY SESSION 16 June 2016 Richard E Greenberg, MD, FACS Chief Urologic Oncology, Fox Chase
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationIMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
More information2019 ASCO Genitourinary Cancers Symposium
2019 ASCO Genitourinary Cancers Symposium Analyst Call February 15, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationMetastatic Bladder Cancer: Immunotherapy. Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-IMIM
Metastatic Bladder Cancer: mmunotherapy Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-MM September 19 th, 2018 Disclosures Advisory role: Genentech, Merck, Pfizer,
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationImmunotherapy and urothelial carcinoma. Yohann Loriot
Immunotherapy and urothelial carcinoma Yohann Loriot Immunothérapie en clinique : Cancers de vessie Où en sommes nous? Données phase I/II FDA «breakthrough designation» Prochaines étapes? Immunothérapie
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationNOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY. Jindřich Fínek LF UK a FN Plzeň
NOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY Jindřich Fínek LF UK a FN Plzeň 1 KARCINOM MOČOVÉHO MĚCHÝŘE INCIDENCE A MORTALITA 2 KARCINOM MOČOVÉHO MĚCHÝŘE ZASTOUPENÍ
More informationBristol-Myers Squibb. Request for Educational Activity (RFE)
Bristol-Myers Squibb Independent Medical Education Request for Educational Activity (RFE) Date RFP Code Therapeutic Area Areas of Interest Educational Design Intended Audience Budget Accreditation Geographic
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationRoche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides
More informationMolecular Targets in Bladder Cancer: PD-1 and Beyond
Molecular Targets in Bladder Cancer: PD-1 and Beyond Sumanta Kumar Pal, M.D. Assistant Professor, Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationRoche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More information